Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease

American Journal of Hematology

Volumn 54, Issue 1, 1997, Pages 12-15

  Kahn, Marc J ^a,b   Scher, Charles ^b   Rozans, Marta ^b   Michaels, Robert K ^a   Leissinger, Cindy ^a   Krause, John ^c  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Tulane School of Public Health and Tropical Medicine   (United States)

Author keywords

Hemoglobinopathy; PCR; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HEMOGLOBINOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STROKE; THROMBOSIS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANEMIA, SICKLE CELL; BLOOD COAGULATION DISORDERS; CEREBROVASCULAR DISORDERS; CHILD; CHILD, PRESCHOOL; FACTOR V; FEMALE; GENE FREQUENCY; HUMANS; INFANT; MALE;

EID: 0031012245     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199701)54:1<12::AID-AJH2>3.0.CO;2-7     Document Type: Article

References (26)

1. Marciniak E: Coagulation inhibitor elicited by thrombin. Science 170:452, 1970.
2. Esmon NL, Owen WG, Esmon CT: Isolation of a membrane-bound cofactor for activation of protein C. J Biol Chem 257:859, 1982.
3. Marlar RA, Kleiss AJ, Griffin JH: Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 59:1067, 1982.
4. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004, 1993.
5. Griffin JH, Evatt B, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989, 1993.
6. Bertina RM, Koelman PC, Koster T, Rosendaal FR, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994.
7. 506 of factor V. Lancet 343:1535, 1994.
8. Powars D, Wilson B, Imbus C, et al: The natural history of stroke in sickle cell disease. Am J Med 65:461, 1978.
9. Ohene-Frempong K: Stroke in sickle cell disease: Demographic, clinical, and therapeutic considerations. Semin Hematol 28:213, 1991.
10. Pavlakis SG: Neurologic complications of sickle cell disease. Adv Pediatr 36:247, 1989.
11. Lindblom B, Holmlund G: Rapid DNA purification for restriction fragment length polymorphism analysis. Gene Anal Tech 5:97, 1988.
12. Zoller B, Dahlback B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536, 1994.
13. Adams RJ: Neurologic complications. In Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): "Sickle Cell Disease: Basic Principles and Clinical Practice." New York: Raven Press, p 615, 1994.
14. Halbmayer WM, Haushofer A, Schon R, Fischer M: The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 5:51, 1994.
15. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A: Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 26:885, 1995.
16. Ridker PM, Hennekens CH, Lindpainter K, et al: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912, 1995.
17. Koster T, Rosendaal FR, de Ronde H, et al: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 342:1503, 1993.
18. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517, 1994.
19. Ma DD, Aboud MR, Williams BG, Isbister JP: Activated protein C resistance (APC) and inherited factor V (FV) missense mutation in patients with venous and arterial thrombosis in haematology clinic. Aust NZ J Med 25:151, 1995.
20. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 49:242, 1995.
21. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504, 1995.
22. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barren J, Lane DA, Grant PJ: Factor V gene mutation and thrombin generation in relation to the development of acute stroke. Arteriosclerosis Thromb Vascular Biol 15:783, 1995.
23. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI: Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 85:1704, 1995.
24. Pottinger P, Sigurdsson F, Berliner N: Detection of the factor V Leiden mutation in a non-selected black population. Blood 87:2091, 1996.
25. Kniffen WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA: The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154:861, 1994.
26. Cripe LD, Moore KD, Dane WH: Structure of the gene for human coagulation factor V. Biochemistry 31:3777, 1992.